Other products in the same Health Canada class (D07AC, R01AD) — coverage varies; not interchangeable
Amcinonide (Cyclocort): general benefit, Not a benefit
Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, Not a benefit
Betamethasone dipropionate (Diprosone): general benefit
Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
13 more in the class list below
Elocom · DIN 00851744 · 0.1% · Cr
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Elocom (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Elocom · DIN 00851744
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2023-05-23 · brand ELOCOM · ATC D07AC13 MOMETASONE · form Cream · route Topical · ingredients MOMETASONE FUROATE 0.1 % · company Organon canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11196 · Verify on the e-Formulary ↗ (DIN 00851744)
Source record
DIN 00851744: Elocom
Raw flags: sec3=Y
Item: 840600109; group id 849; item number 2064; lccId None; manufacturer id OCI
Source form: Cr; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.7393; ministry $0.5542
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851744
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11196Interchangeable products
Taro-Mometasone · DIN 02367157 · $0.5542
Shortage status: resolved shortage (ended 2024-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00851744
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Mometasone · DIN 02367157 · 0.1% · Cr
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Mometasone · DIN 02367157
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2012-02-29
Health Canada: Marketed since 2011-06-08 · brand TARO-MOMETASONE CREAM · ATC D07AC13 MOMETASONE · form Cream · route Topical · ingredients MOMETASONE FUROATE 0.1 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Taro-Mometasone: Formulary list price $0.5542/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5542 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85196 · Verify on the e-Formulary ↗ (DIN 02367157)
Source record
DIN 02367157: Taro-Mometasone
Raw flags: sec3=Y
Item: 840600109; group id 849; item number 2064; lccId None; manufacturer id TAR
Source form: Cr; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.5542; ministry $0.5542
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02367157
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85196Interchangeable products
Elocom · DIN 00851744 · $0.5542
Shortage status: resolved shortage (ended 2026-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02367157
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Elocom · DIN 00871095 · 0.1% · Lot
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Elocom (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Elocom · DIN 00871095
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-06-21 · brand ELOCOM · ATC D07AC13 MOMETASONE · form Lotion · route Topical · ingredients MOMETASONE FUROATE 0.1 % · company Organon canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11443 · Verify on the e-Formulary ↗ (DIN 00871095)
Source record
DIN 00871095: Elocom
Raw flags: sec3=Y
Item: 840600111; group id 849; item number 2065; lccId None; manufacturer id OCI
Source form: Lot; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.5255; ministry $0.3627
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00871095
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11443Interchangeable products
Taro-Mometasone · DIN 02266385 · $0.3627
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00871095
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Mometasone · DIN 02266385 · 0.1% · Lot
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Mometasone · DIN 02266385
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2014-07-30
Health Canada: Marketed since 2009-12-01 · brand TARO-MOMETASONE LOTION · ATC D07AC13 MOMETASONE · form Lotion · route Topical · ingredients MOMETASONE FUROATE 0.1 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Taro-Mometasone: Formulary list price $0.3627/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3627 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75180 · Verify on the e-Formulary ↗ (DIN 02266385)
Source record
DIN 02266385: Taro-Mometasone
Raw flags: sec3=Y
Item: 840600111; group id 849; item number 2065; lccId None; manufacturer id TAR
Source form: Lot; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.3627; ministry $0.3627
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266385
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75180Interchangeable products
Elocom · DIN 00871095 · $0.3627
Shortage status: resolved shortage (ended 2026-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266385
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Elocom · DIN 00851736 · 0.1% · Oint
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Elocom (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Elocom · DIN 00851736
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-08-18 · brand ELOCOM · ATC D07AC13 MOMETASONE · form Ointment · route Topical · ingredients MOMETASONE FUROATE 0.1 % · company Organon canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11444 · Verify on the e-Formulary ↗ (DIN 00851736)
Source record
DIN 00851736: Elocom
Raw flags: sec3=Y
Item: 840600110; group id 849; item number 2066; lccId None; manufacturer id OCI
Source form: Oint; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.7342; ministry $0.2252
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851736
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11444Interchangeable products
Ratio-Mometasone · DIN 02248130 · $0.2252
Shortage status: resolved shortage (ended 2025-02-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00851736
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ratio-Mometasone · DIN 02248130 · 0.1% · Oint
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Mometasone · DIN 02248130
Manufacturer: Ratiopharm Inc.; listing date 2004-07-20
Health Canada: Marketed since 2018-01-17 · brand TEVA-MOMETASONE · ATC D07AC13 MOMETASONE · form Ointment · route Topical · ingredients MOMETASONE FUROATE 0.1 % · company Teva canada limited · schedule Prescription
Ratio-Mometasone: Formulary list price $0.2252/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2252 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72459 · Verify on the e-Formulary ↗ (DIN 02248130)
Source record
DIN 02248130: Ratio-Mometasone
Raw flags: sec3=Y
Item: 840600110; group id 849; item number 2066; lccId None; manufacturer id RPH
Source form: Oint; strength: 0.1%
Recorded listing: General benefit
Source prices (unrounded): $0.2252; ministry $0.2252
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248130
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72459Interchangeable products
Elocom · DIN 00851736 · $0.2252
Shortage status: resolved shortage (ended 2025-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248130
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Asmanex Twisthaler: Formulary list price $42.4320/unit (unit not stated in source; not the patient's cost)
Ministry pays: $42.4320 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67513 · Verify on the e-Formulary ↗ (DIN 02243595)
Source record
DIN 02243595: Asmanex Twisthaler
Raw flags: sec3=Y
Item: 680400108; group id 717; item number 1772; lccId None; manufacturer id OCI
Source form: Pd Inh-60 Dose Pk; strength: 200mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $42.4320; ministry $42.4320
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243595
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67513
Therapeutic Notes (formulary)
NOTES: The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids. The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents. Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.
Shortage status: anticipated shortage (last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243595
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Asmanex Twisthaler: Formulary list price $42.4320/unit (unit not stated in source; not the patient's cost)
Ministry pays: $42.4320 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67514 · Verify on the e-Formulary ↗ (DIN 02243596)
Source record
DIN 02243596: Asmanex Twisthaler
Raw flags: sec3=Y
Item: 680400109; group id 717; item number 1771; lccId None; manufacturer id OCI
Source form: Pd Inh-30 Dose Pk; strength: 400mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $42.4320; ministry $42.4320
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243596
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67514
Therapeutic Notes (formulary)
NOTES: The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids. The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents. Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.
Shortage status: anticipated shortage (last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243596
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Mometasone · DIN 02403587 · 50mcg/Dose · Nas Sp-140 Dose Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Mometasone · DIN 02403587
Manufacturer: Apotex Inc.; listing date 2013-11-28
Health Canada: Marketed since 2013-03-25 · brand APO-MOMETASONE · ATC R01AD09 MOMETASONE · form Spray (metered-dose) · route Nasal · ingredients MOMETASONE FUROATE 50 MCG/ACT · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88837 · Verify on the e-Formulary ↗ (DIN 02403587)
Source record
DIN 02403587: Apo-Mometasone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520800041; group id 599; item number 1559; lccId None; manufacturer id APX
Source form: Nas Sp-140 Dose Pk; strength: 50mcg/Dose
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $21.6900; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403587
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88837Interchangeable products
Mometasone · DIN 02519127 · not recorded
Mometasone · DIN 02551756 · not recorded
Nasonex · DIN 02238465 · not recorded
Sandoz Mometasone · DIN 02449811 · not recorded
Teva-Mometasone · DIN 02475863 · not recorded
Shortage status: shortage reported ended 2026-07-09 (report last updated 2026-07-09); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403587
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mometasone · DIN 02519127 · 50mcg/Dose · Nas Sp-140 Dose Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mometasone · DIN 02519127
Manufacturer: Sanis Health Inc.; listing date 2022-04-29
Health Canada: Marketed since 2022-05-30 · brand MOMETASONE · ATC R01AD09 MOMETASONE · form Spray (metered-dose) · route Nasal · ingredients MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCG/ACT · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100840 · Verify on the e-Formulary ↗ (DIN 02519127)
Source record
DIN 02519127: Mometasone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520800041; group id 599; item number 1559; lccId None; manufacturer id SAI
Source form: Nas Sp-140 Dose Pk; strength: 50mcg/Dose
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $21.6900; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519127
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100840Interchangeable products
Apo-Mometasone · DIN 02403587 · not recorded
Mometasone · DIN 02551756 · not recorded
Nasonex · DIN 02238465 · not recorded
Sandoz Mometasone · DIN 02449811 · not recorded
Teva-Mometasone · DIN 02475863 · not recorded
Shortage status: resolved shortage (ended 2024-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519127
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mometasone · DIN 02551756 · 50mcg/Dose · Nas Sp-140 Dose Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mometasone · DIN 02551756
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-07-31
Health Canada: Marketed since 2025-06-06 · brand MOMETASONE · ATC R01AD09 MOMETASONE · form Spray (metered-dose) · route Nasal · ingredients MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCG/ACT · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104047 · Verify on the e-Formulary ↗ (DIN 02551756)
Source record
DIN 02551756: Mometasone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520800041; group id 599; item number 1559; lccId None; manufacturer id SIV
Source form: Nas Sp-140 Dose Pk; strength: 50mcg/Dose
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $21.6860; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02551756
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104047Interchangeable products
Apo-Mometasone · DIN 02403587 · not recorded
Mometasone · DIN 02519127 · not recorded
Nasonex · DIN 02238465 · not recorded
Sandoz Mometasone · DIN 02449811 · not recorded
Teva-Mometasone · DIN 02475863 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02551756
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nasonex · DIN 02238465 · 50mcg/Dose · Nas Sp-140 Dose Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
Savings card: RxHelp ONE lists Nasonex (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Nasonex · DIN 02238465
Manufacturer: Organon Canada Inc.; listing date 2013-11-28
Health Canada: Marketed since 2022-04-14 · brand NASONEX · ATC R01AD09 MOMETASONE · form Spray (metered-dose) · route Nasal · ingredients MOMETASONE FUROATE 50 MCG/ACT · company Organon canada inc. · schedule Prescription
Nasonex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61885 · Verify on the e-Formulary ↗ (DIN 02238465)
Source record
DIN 02238465: Nasonex
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520800041; group id 599; item number 1559; lccId None; manufacturer id OCI
Source form: Nas Sp-140 Dose Pk; strength: 50mcg/Dose
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238465
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61885Interchangeable products
Apo-Mometasone · DIN 02403587 · not recorded
Mometasone · DIN 02519127 · not recorded
Mometasone · DIN 02551756 · not recorded
Sandoz Mometasone · DIN 02449811 · not recorded
Teva-Mometasone · DIN 02475863 · not recorded
Shortage status: resolved shortage (ended 2024-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02238465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Mometasone · DIN 02449811 · 50mcg/Dose · Nas Sp-140 Dose Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Mometasone · DIN 02449811
Manufacturer: Sandoz Canada Inc.; listing date 2017-01-31
Health Canada: Marketed since 2016-07-27 · brand SANDOZ MOMETASONE · ATC R01AD09 MOMETASONE · form Spray (metered-dose) · route Nasal · ingredients MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) 50 MCG/ACT · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93568 · Verify on the e-Formulary ↗ (DIN 02449811)
Source record
DIN 02449811: Sandoz Mometasone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520800041; group id 599; item number 1559; lccId None; manufacturer id SDZ
Source form: Nas Sp-140 Dose Pk; strength: 50mcg/Dose
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $21.6860; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449811
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93568Interchangeable products
Apo-Mometasone · DIN 02403587 · not recorded
Mometasone · DIN 02519127 · not recorded
Mometasone · DIN 02551756 · not recorded
Nasonex · DIN 02238465 · not recorded
Teva-Mometasone · DIN 02475863 · not recorded
Shortage status: resolved shortage (ended 2024-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449811
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Mometasone · DIN 02475863 · 50mcg/Dose · Nas Sp-140 Dose Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Mometasone · DIN 02475863
Manufacturer: Teva Canada Limited; listing date 2018-11-29
Health Canada: Marketed since 2018-10-02 · brand TEVA-MOMETASONE · ATC R01AD09 MOMETASONE · form Spray (metered-dose) · route Nasal · ingredients MOMETASONE FUROATE 50 MCG/ACT · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96662 · Verify on the e-Formulary ↗ (DIN 02475863)
Source record
DIN 02475863: Teva-Mometasone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520800041; group id 599; item number 1559; lccId None; manufacturer id TEV
Source form: Nas Sp-140 Dose Pk; strength: 50mcg/Dose
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $21.6900; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475863
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96662Interchangeable products
Apo-Mometasone · DIN 02403587 · not recorded
Mometasone · DIN 02519127 · not recorded
Mometasone · DIN 02551756 · not recorded
Nasonex · DIN 02238465 · not recorded
Sandoz Mometasone · DIN 02449811 · not recorded
Shortage status: active shortage (reported 2025-02-12, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475863
Shortage record checked 2026-09-13T08:10:21.292534+00:00
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Asmanex Twisthaler · DIN 09857431
Manufacturer: Organon Canada Inc.; listing date 2012-12-21
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09857431: Asmanex Twisthaler
Raw flags: sec3=Y
Item: 680400110; group id 717; item number 1773; lccId None; manufacturer id OCI
Source form: Pd Inh-60 Dose Pk; strength: 400mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $84.8280; ministry $84.8280
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857431
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Therapeutic Notes (formulary)
NOTES: The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids. The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents. Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857431
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 627 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 627 required
Write on scriptLU code 627 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 627
Reason for Use code 627
For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Enerzair Breezhaler · DIN 02501244
Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28
Health Canada: Marketed since 2020-11-05 · brand ENERZAIR BREEZHALER · ATC R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE, R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE · form Capsule · route Inhalation · ingredients MOMETASONE FUROATE 160 MCG, GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE) 50 MCG, INDACATEROL (INDACATEROL ACETATE) 150 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Enerzair Breezhaler: Formulary list price $3.4277/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.4277 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087 · Verify on the e-Formulary ↗ (DIN 02501244)
Source record
DIN 02501244: Enerzair Breezhaler
Raw flags: sec12=Y, sec3=Y
Item: 680400122; group id 713; item number 1763; lccId 00355; manufacturer id NOV
Source form: Inh Pd-Cap; strength: 150mcg & 50mcg & 160mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.4277; ministry $3.4277
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02501244
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087
Shortage status: resolved shortage (ended 2024-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02501244
Shortage record checked 2026-09-13T08:10:21.292534+00:00
INDACATEROL ACETATE & MOMETASONE FUROATE
All strengths: Limited Use — Reason for Use code 626 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 626 required
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (D07AC, R01AD) — coverage varies; not interchangeable
Amcinonide (Cyclocort): general benefit, Not a benefit
Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, Not a benefit
Betamethasone dipropionate (Diprosone): general benefit
Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit
Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19
Write on scriptLU code 626 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 626
Reason for Use code 626
For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Atectura Breezhaler · DIN 02498685
Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28
Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 80 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Atectura Breezhaler: Formulary list price $1.0731/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0731 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98847 · Verify on the e-Formulary ↗ (DIN 02498685)
Source record
DIN 02498685: Atectura Breezhaler
Raw flags: sec12=Y, sec3=Y
Item: 680400119; group id 714; item number 1766; lccId 00354; manufacturer id NOV
Source form: Inh Pd-Cap; strength: 150mcg & 80mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.0731; ministry $1.0731
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498685
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98847
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498685
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19
Write on scriptLU code 626 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 626
Reason for Use code 626
For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Atectura Breezhaler · DIN 02498693
Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28
Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 320 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Atectura Breezhaler: Formulary list price $1.8473/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.8473 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98848 · Verify on the e-Formulary ↗ (DIN 02498693)
Source record
DIN 02498693: Atectura Breezhaler
Raw flags: sec12=Y, sec3=Y
Item: 680400121; group id 714; item number 1765; lccId 00354; manufacturer id NOV
Source form: Inh Pd-Cap; strength: 150mcg & 320mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.8473; ministry $1.8473
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498693
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98848
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498693
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-02
Write on scriptLU code 626 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 626
Reason for Use code 626
For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Atectura Breezhaler · DIN 02498707
Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28
Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE, R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 160 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Atectura Breezhaler: Formulary list price $1.3419/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3419 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98849 · Verify on the e-Formulary ↗ (DIN 02498707)
Source record
DIN 02498707: Atectura Breezhaler
Raw flags: sec12=Y, sec3=Y
Item: 680400120; group id 714; item number 1764; lccId 00354; manufacturer id NOV
Source form: Inh Pd-Cap; strength: 150mcg & 160mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.3419; ministry $1.3419
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498707
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98849
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02498707
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330
For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Zenhale · DIN 02361752
Manufacturer: Organon Canada Inc.; listing date 2012-02-29
Health Canada: Marketed since 2022-02-22 · brand ZENHALE · ATC R03AK09 FORMOTEROL AND MOMETASONE, R03AK09 FORMOTEROL AND MOMETASONE · form Aerosol (metered-dose) · route Inhalation · ingredients MOMETASONE FUROATE 100 MCG/ACT, FORMOTEROL FUMARATE DIHYDRATE 5 MCG/ACT · company Organon canada inc. · schedule Prescription
Zenhale: Formulary list price $129.8900/unit (unit not stated in source; not the patient's cost)
Ministry pays: $129.8900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84680 · Verify on the e-Formulary ↗ (DIN 02361752)
Source record
DIN 02361752: Zenhale
Raw flags: sec12=Y, sec3=Y
Item: 121200095; group id 230; item number 0409; lccId 00220; manufacturer id OCI
Source form: Metered Dose Inh-120 Dose Pk; strength: 100mcg & 5mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $129.8900; ministry $129.8900
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361752
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84680
Shortage status: discontinued (2025-08-26, reported by ORGANON CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361752
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330
For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Zenhale · DIN 02361760
Manufacturer: Organon Canada Inc.; listing date 2012-02-29
Health Canada: Marketed since 2022-04-05 · brand ZENHALE · ATC R03AK09 FORMOTEROL AND MOMETASONE, R03AK09 FORMOTEROL AND MOMETASONE · form Aerosol (metered-dose) · route Inhalation · ingredients MOMETASONE FUROATE 200 MCG/ACT, FORMOTEROL FUMARATE DIHYDRATE 5 MCG/ACT · company Organon canada inc. · schedule Prescription
Zenhale: Formulary list price $157.3900/unit (unit not stated in source; not the patient's cost)
Ministry pays: $157.3900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84681 · Verify on the e-Formulary ↗ (DIN 02361760)
Source record
DIN 02361760: Zenhale
Raw flags: sec12=Y, sec3=Y
Item: 121200096; group id 230; item number 0410; lccId 00220; manufacturer id OCI
Source form: Metered Dose Inh-120 Dose Pk; strength: 200mcg & 5mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $157.3900; ministry $157.3900
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361760
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84681
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361760
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE
Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL
12:12 Sympathomimetic (Adrenergic) Agents
Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered
Matched class: 52:08 Anti-Inflammatory Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE
Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE
52:08 Anti-Inflammatory Agents
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08
and 2 more
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered
Matched class: 68:04 Corticosteroids
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, TRIAMCINOLONE ACETONIDE
Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE
68:04 Corticosteroids
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04
and 3 more
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered
Matched class: 84:06 Anti-Inflammatory
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE
Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE
84:06 Anti-Inflammatory
· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint
· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06
and 5 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330
INDICATIONS AND CLINICAL USE
Asthma
SYMBICORT TURBUHALER (budesonide and formoterol fumarate dihydrate) is indicated
for the treatment of asthma in patients 12 years and older with reversible obstructive airways
disease.
PM: https://pdf.hres.ca/dpd_pm/00059997.PDF; date February 8, 2021; DIN 02245385; fetched 2026-09-10
Product monographFLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1)
Page 3 of 74
Asthma
BREO ELLIPTA 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the
once-daily maintenance treatment of asthma in patients aged 18 years and older with
reversible obstructive airways disease.
PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications
ELOCOM® (mometasone furoate) Cream, Ointment and Lotion 0.1%:
• are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-
responsive dermatoses such as psoriasis and atopic dermatitis. The lotion formulation may be
applied to scalp lesions.
• can be used for a maximum of 3 weeks duration on the body and of 5 days duration on the face,
scalp, axillae and scrotum.
1.1. Pediatrics
Pediatrics (<18 years of age): Safety and efficacy of ELOCOM have not been established in pediatric
patients (see 7. Warnings and Precautions, 7.1. Special Populations, 7.1.3. Pediatrics).
1.2. Geriatrics
Geriatrics (≥ 65 years of age): No overall differences in safety and effectiveness were observed between
subjects greater than 65 years of age and younger subjects receiving ELOCOM Cream or Ointment.
Clinical trials of ELOCOM Lotion did not include sufficient numbers of subjects aged 65 years and older
to determine whether they respond differently from younger subjects. Geriatric patients may be more
susceptible to the potential effects of systemic absorption. Decreased hepatic or renal function in the
elderly may delay elimination (see …
https://pdf.hres.ca/dpd_pm/00081816.PDF
PM date: 2025-09-19
Source product: ELOCOM; DIN 00851736; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
ENERZAIR BREEZHALER (indacaterol / glycopyrronium / mometasone furoate) is indicated as a
maintenance treatment of asthma in adult patients not adequately controlled with a maintenance
combination of a long-acting beta 2 -agonist and a medium or high dose of an inhaled corticosteroid who
experienced one or more asthma exacerbations in the previous 12 months.
ENERZAIR BREEZHALER is not indicated for the relief of acute bronchospasm (see General).
1.1 Pediatrics
Pediatrics (<18 years of age): The safety and efficacy of ENERZAIR BREEZHALER in pediatric patients
below 18 years of age have not been established; therefore, Health Canada has not authorized an
indication for pediatric use.
1.2 Geriatrics
Geriatrics (≥ 65 years of age): No dose adjustment is required in patients 65 years of age or older (see
10.3 Pharmacokinetics).
https://pdf.hres.ca/dpd_pm/00063748.PDF
PM date: Jul 2, 2020
Source product: ENERZAIR BREEZHALER; DIN 02501244; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
ATECTURA BREEZHALER (indacaterol/mometasone furoate) is a combination of a long-acting beta2-
adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once-daily maintenance
treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive
airways disease.
ATECTURA BREEZHALER should be prescribed for patients not adequately controlled on a long-term
asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a
LABA and an ICS.
ATECTURA BREEZHALER is not indicated for patients whose asthma can be managed by occasional use
of a rapid onset, short duration, inhaled beta2-agonist or for patients whose asthma can be successfully
managed by ICS along with occasional use of a rapid onset, short duration, inhaled beta2-agonist.
ATECTURA BREEZHALER is not indicated for the relief of acute bronchospasm (see General).
1.1 Pediatrics
Pediatrics (under 12 years of age): The safety and efficacy of ATECTURA BREEZHALER in pediatric
patients less than 12 years of age has not been established, therefore, Health Canada has not authorized
an indication for this age group.
1.2 …
https://pdf.hres.ca/dpd_pm/00063537.PDF
PM date: May 5, 2020
Source product: ATECTURA BREEZHALER; DIN 02498685; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 Indications
ZENHALE® (mometasone furoate / formoterol fumarate dihydrate inhalation aerosol), is a combination
of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for:
• the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway
disease.
ZENHALE should be prescribed for patients not adequately controlled on a long-term asthma control
medication, such as an ICS, or whose disease severity clearly warrants treatment with both an ICS and a
LABA.
ZENHALE is not indicated for patients whose asthma can be managed by occasional use of a rapid onset,
short duration, inhaled beta2-agonist, or for patients whose asthma can be successfully managed by
inhaled corticosteroids along with occasional use of a rapid onset, short duration, inhaled beta2-agonist.
Once asthma control has been achieved and maintained, assess the patient at regular intervals.
ZENHALE is not indicated for the relief of acute bronchospasm.
1.1 Pediatrics
Pediatrics (< 12 years of age): The safety and efficacy of the available strengths of ZENHALE have not
been established in children under 12 years of age.
1.2 Geria…
https://pdf.hres.ca/dpd_pm/00080784.PDF
PM date: 2025-06-09
Source product: ZENHALE; DIN 02361752; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Elocom · DIN 00871095
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00871095
Apo-Mometasone · DIN 02403587
Shortage status: shortage reported ended 2026-07-09 (report last updated 2026-07-09); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403587
Teva-Mometasone · DIN 02475863
Shortage status: active shortage (reported 2025-02-12, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475863
Zenhale · DIN 02361760
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361760
For Apo-Mometasone, Mometasone, Nasonex, Sandoz Mometasone, Teva-Mometasone: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.